<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01983514</url>
  </required_header>
  <id_info>
    <org_study_id>SMR-2727</org_study_id>
    <nct_id>NCT01983514</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults</brief_title>
  <official_title>Intranasal (Optinose Bidirectional Nose-to-brain Device) Versus Intravenous Slow Infusion of Oxytocin - a Randomized, Placebo- Controlled Double-blind, Double-dummy 4-period Cross-over Study in Healthy Adult Volunteers Evaluating Brain Functional Magnetic Resonance Imaging Changes, Cognitive Response, Heart Rate Variability, Plasma Pharmacokinetics and Saliva Concentration After Single-dose Oxytocin 8 or 24 International Units (IU) Intranasally or 1 IU as Slow Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OptiNose AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OptiNose AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate
      lactation in breastfeeding women. The intranasal administration of OT has recently attracted
      attention as a potential novel treatment in several psychiatric disorders including autism.
      However, given the anatomy of the nasal cavity, the current design of nasal sprays would be
      expected to provide an inadequate delivery of medication to the areas of the nasal cavity
      where direct transport into the brain via the olfactory nerve could potentially occur.
      OptiNose has developed an intranasal delivery device that provides improved reproducibility
      of nasal delivery, improved deposition to the upper posterior regions of the nasal cavity
      where the olfactory nerve innervates the nasal cavity.

      The primary objective of this study is to identify any differences between single dose 8 or
      24 international units (IU) oxytocin delivered intranasally with the optimised OptiNose
      device and 1 IU oxytocin administered as slow intravenous infusion in healthy volunteers.
      This will be measured in terms of brain activity as measured with functional magnetic
      resonance imaging (fMRI), performance on cognitive tests, and physiological markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aim 1a: Brain activity</measure>
    <time_frame>30 minutes after oxytocin/placebo administration</time_frame>
    <description>Scanning procedures for functional magnetic resonance imaging (fMRI) will include a functional scan during a social cognition task and structural connectivity during rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 1b: Performance on a social cognition test</measure>
    <time_frame>45 mins after oxytocin/placebo administration</time_frame>
    <description>Participants will complete a task evaluating emotional expressions (either happy expressions, fear expressions or neutral expressions). These stimuli are identical to those published previously by Leknes et al., (2012).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 1c: Heart rate variability</measure>
    <time_frame>20 minutes after oxytocin placebo administration</time_frame>
    <description>Electrocardiogram data will be collected to assess heart rate variability, a measure of cardiac autonomic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 1d: Eyetracking</measure>
    <time_frame>20 minutes after oxytocin placebo administration</time_frame>
    <description>An eyetracking device will measure eyegaze and pupillometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of oxytocin</measure>
    <time_frame>5 minutes prior to oxytocin/placebo administration</time_frame>
    <description>Blood will be collected to assess levels of oxytocin present in peripheral blood to measure PK profile of 8 and 24 international units (IU) oxytocin delivered with OptiNose device and of 1 IU oxytocin after slow intravenous (IV) infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cortisol</measure>
    <time_frame>20 minutes before fMRI procedure</time_frame>
    <description>Blood will be drawn at various intervals for the pharmacokinetic analysis of plasma cortisol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxytocin levels in saliva</measure>
    <time_frame>20 prior to fMRI procedure</time_frame>
    <description>Saliva will be collected for pharmacokinetic analysis of oxytocin and cortisol in saliva.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol levels in saliva</measure>
    <time_frame>20 minutes prior to fMRI procedure</time_frame>
    <description>Saliva will be collected for pharmacokinetic analysis of oxytocin and cortisol in saliva.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy Male Adults</condition>
  <arm_group>
    <arm_group_label>1 international unit (IU) intravenous oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8IU intranasal oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24IU intranasal oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8IU intranasal oxytocin</intervention_name>
    <arm_group_label>8IU intranasal oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>24 IU intranasal oxytocin</intervention_name>
    <arm_group_label>24IU intranasal oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 IU intravenous oxytocin</intervention_name>
    <arm_group_label>1 international unit (IU) intravenous oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male subjects aged 18 to 35 years inclusive.

          -  Subjects must be in good general health, as determined by the investigator.

          -  Subject's pre-study physical examination, vital signs and electrocardiogram (ECG) are
             normal or do not show any clinically significant abnormalities as determined by the
             investigator. Vital signs must not have any clinically significant deviations outside
             of the following ranges when measured sitting after 5 minutes rest:

               1. Heart rate: 40 to 90 beats per minute

               2. Systolic blood pressure (BP): 90 to 140 mmHg

               3. Diastolic BP: 50 to 90 mmHg

               4. Oral temperature: 36.0 to 37.5Â°C

               5. Respiratory rate: 12 - 18 breaths per minute

          -  Body Mass Index (BMI) of 18.5 - 29.9 kg/m2 (both inclusive)

          -  Subjects must be able to communicate well with the Investigator, to understand and
             comply with the requirements of the study, and understand and sign the written
             informed consent

          -  Provision of written informed consent.

        Exclusion Criteria:

        An ear, nose and throat (ENT) specialist will inspect the noses of all individuals who
        enter the study.

        In order to participate in the study subjects must not meet any of the following exclusion
        criteria;

          -  Individuals showing major septal deviation or a significantly altered nasal
             epithelium.

          -  Participants with evidence of previous nasal disease, surgery, and dependence on
             inhaled drugs.

          -  Individuals with current significant nasal congestion due to common colds.

          -  Subjects with a clinically relevant history of significant hepatic, renal, endocrine,
             cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological or
             metabolic disorder.

          -  Subjects with current or history of, any clinically significant disease or condition
             known to interfere with the absorption, distribution, metabolism or excretion of
             drugs.

          -  Subject is taking any regular prescribed or over-the-counter (OTC) medications
             including vitamin supplements and herbal remedies. There must be at least 14 days
             between stopping these products and the first dose of study medication).

          -  Systemic illness requiring treatment within 2 weeks prior to Study Day 1.

          -  History of significant drug or alcohol abuse (as per a self-report measure /
             instrument; World Health Organisation criteria/Alcohol use disorders identification
             test/Drug use disorders identification test). Subjects with a positive screen for
             alcohol or drugs of abuse at screening/admission will be excluded from participation
             in the study.

          -  Self-reported significant psychiatric conditions.

          -  Any abnormal laboratory values outside normal range, and which is clinically
             significant as deemed by investigator.

          -  Full scale intelligence quotient (IQ) &lt; 75 (due to the prerequisite ability to
             complete self report measures).

          -  Known allergic reactions or hypersensitivity to any component of the study medication
             in the nasal spray, such as E216, E218 and chlorobutanol hemihydrate.

          -  Participation in any (other) clinical trial with an investigational medicinal product
             or medical device within 3 months prior to randomisation.

          -  Current evidence of any mental or physical disorder or collaboration attitude which,
             in the judgment of the investigator makes the subject unsuitable for enrolment, and/or
             may interfere with the study evaluations or affect subject's safety.

          -  Subjects with any metal implants.

          -  Subjects with claustrophobia.

          -  Other unspecified reasons that, in the opinion of the Investigator or the sponsor make
             the subject unsuitable for enrolment.

          -  Subjects with female partners of child-bearing potential must use an adequate form of
             contraception prior to entry into the study until three months following the
             post-study medical visit. Subjects must not have a partner who is either pregnant or
             breastfeeding for the duration of the study. Adequate contraception is defined as the
             usage by the female partner of any form of hormonal contraception or intra-uterine
             device (which should be established prior to the start of the study) plus usage by one
             of the partners of an additional spermicide- containing barrier method of
             contraception.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole A Andreassen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research - TOP Study</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.med.uio.no/norment/english/</url>
    <description>Click here for more information about NORMENT: Norwegian Centre for Mental Disorders Research</description>
  </link>
  <reference>
    <citation>Leknes S, Wessberg J, Ellingsen DM, Chelnokova O, Olausson H, Laeng B. Oxytocin enhances pupil dilation and sensitivity to 'hidden' emotional expressions. Soc Cogn Affect Neurosci. 2013 Oct;8(7):741-9. doi: 10.1093/scan/nss062. Epub 2012 May 29.</citation>
    <PMID>22648957</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>fMRI</keyword>
  <keyword>social cognition</keyword>
  <keyword>heart rate variability</keyword>
  <keyword>pupillometry</keyword>
  <keyword>eye tracking</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

